Home / Deep Research / Clouston Syndrome

Clouston Syndrome

Clouston Syndrome (Hidrotic Ectodermal Dysplasia 2; HED2): Comprehensive Disease Characteristics Report

2026-04-24
Falcon MONDO:0007510 Model: Edison Scientific Literature 23 citations

Clouston Syndrome (Hidrotic Ectodermal Dysplasia 2; HED2): Comprehensive Disease Characteristics Report

Executive summary (current understanding)

Clouston syndrome is a rare autosomal dominant ectodermal dysplasia primarily affecting hair, nails, and palmoplantar skin, classically presenting with the triad of nail dystrophy, hypotrichosis/alopecia, and palmoplantar hyperkeratosis, typically with normal sweating and normal dentition (OMIM #129500). Core evidence includes a large 2023 multi-generation Chinese pedigree study identifying a novel GJB6 variant and detailing age-related clinical evolution, and mechanistic 2024 synthesis highlighting connexin hemichannel gain-of-function as a therapeutic target. (huang2023anovelvariant pages 1-2, baris2008anovelgjb6 pages 1-3, yasarbas2024connexinsinepidermal pages 15-17)

1. Disease information

1.1 Disease overview

Clouston syndrome (hidrotic ectodermal dysplasia type 2) is an ectodermal dysplasia characterized by the triad of nail dystrophy, partial-to-complete alopecia/hypotrichosis, and palmoplantar hyperkeratosis, with no sweat gland or tooth abnormalities in typical cases. (huang2023anovelvariant pages 1-2)

Direct abstract quote (2023, Frontiers of Medicine): “Clouston syndrome (OMIM #129500), also known as hidrotic ectodermal dysplasia type 2, is a rare autosomal dominant skin disorder.” (huang2023anovelvariant pages 1-2)

1.2 Key identifiers (available from retrieved full text)

1.3 Synonyms / alternative names

1.4 Evidence source type

Most disease information here is derived from aggregated disease-level resources embedded in primary/review literature (OMIM-linked descriptions) and from individual/family-based studies (case/family cohorts with molecular confirmation). (huang2023anovelvariant pages 1-2, kutkowskakazmierczak2015phenotypicvariabilityin pages 1-3, baris2008anovelgjb6 pages 1-3)

2. Etiology

2.1 Primary causal factors

Genetic etiology: Pathogenic variants in GJB6 (encoding connexin 30, Cx30) cause Clouston syndrome. (baris2008anovelgjb6 pages 1-3, huang2023anovelvariant pages 1-2)

  • Baris et al. (2008) states positional cloning identified GJB6 on chromosome 13q12 as the causative gene; the disorder is autosomal dominant with hair, nail, and palmoplantar findings and normal sweating/dentition. (baris2008anovelgjb6 pages 1-3)

2.2 Risk factors

No credible environmental/toxic/infectious risk factors were identified in the retrieved corpus.

2.3 Protective factors

No protective genetic or environmental factors were identified in the retrieved corpus.

2.4 Gene–environment interactions

No gene–environment interaction evidence was identified in the retrieved corpus.

3. Phenotypes

3.1 Core phenotype spectrum

Canonical triad and typical sparing of sweat glands/teeth - Nail dystrophy, hypotrichosis/alopecia, palmoplantar hyperkeratosis; sweating and dentition typically normal. (huang2023anovelvariant pages 1-2, baris2008anovelgjb6 pages 1-3)

Detailed phenotypes from a large 2023 pedigree (China; 60 individuals, 22 affected): - Hair: absent/sparse scalp hair, eyebrows, eyelashes from birth in the proband; severity may intensify with age. (huang2023anovelvariant pages 1-2) - Nails: curvature increase by ~5–6 months; thickened/shortened/slow-growing by ~1 year in the proband. (huang2023anovelvariant pages 1-2) - Palmoplantar keratoderma/hyperkeratosis: developed gradually after puberty in the proband; palms mild, soles more obvious. (huang2023anovelvariant pages 1-2, huang2023anovelvariant pages 2-4) - Sweat glands/teeth/hearing/cognition: reported as normal in that pedigree. (huang2023anovelvariant pages 1-2)

Novel/expanded phenotype (2023 pedigree): “all nail needling pain” (cold-triggered nail pain is described in the study body) (huang2023anovelvariant pages 1-2, huang2023anovelvariant pages 4-7)

3.2 Onset, severity, progression

3.3 Suggested HPO terms (non-exhaustive; for knowledge base population)

(ontology suggestions; not claims of frequency unless noted above) - Nail dystrophy: HP:0002164 - Onycholysis: HP:0001806 - Palmoplantar keratoderma: HP:0000972 - Alopecia: HP:0001596 - Hypotrichosis: HP:0001006 - Sparse eyebrows: HP:0000535 - Sparse eyelashes: HP:0000653 - Normal sweating (as absence of hypohidrosis): HP:0000970 is hypohidrosis (use negation/absence where supported) (baris2008anovelgjb6 pages 1-3)

3.4 Quality of life impact

The retrieved sources did not include standardized quality-of-life instruments. However, clinically, nail dystrophy and palmoplantar hyperkeratosis can plausibly impair function and cause pain; in the 2023 pedigree, cold-triggered nail pain was severe (NRS values described in the paper body). (huang2023anovelvariant pages 4-7)

4. Genetic / molecular information

4.1 Causal gene

4.2 Pathogenic variants (reported in retrieved primary literature)

Variants repeatedly referenced as confirmed disease-causing in Clouston syndrome: - G11R, V37E, A88V, D50N (huang2023anovelvariant pages 1-2)

Examples with specific evidence and mapping - D50N: Baris et al. (2008) reports heterozygous nucleotide 148 G>A leading to D50N in the first extracellular loop (E1) in a mother and son with HED2. (baris2008anovelgjb6 pages 1-3) - p.Gly11Arg (c.31G>C): reported in a Polish family with Clouston syndrome; authors emphasize diagnostic difficulty due to variability. (kutkowskakazmierczak2015phenotypicvariabilityin pages 3-5) - c.134G>C (p.G45A): novel heterozygous missense variant reported in a large Chinese pedigree; absent from gnomAD in the study’s report and classified as likely pathogenic by ACMG criteria. (huang2023anovelvariant pages 1-2, huang2023anovelvariant pages 2-4)

Domain localization (from 2023 synthesis within the pedigree paper): - G11R in cytoplasmic N-terminus; V37E in M1; A88V in M2; D50N in E1; and the newly reported G45A in an adjacent membrane region. (huang2023anovelvariant pages 7-8)

4.3 Variant consequences (functional class)

A current mechanistic theme is hemichannel gain-of-function (“hyperactive hemichannels”) for at least some Cx30 mutants (e.g., A88V, G11R) with downstream ATP/Ca2+ signaling effects in keratinocytes, alongside trafficking/gap-junction effects that may be context dependent. (yasarbas2024connexinsinepidermal pages 11-12, yasarbas2024connexinsinepidermal pages 15-17)

4.4 Modifier genes / epigenetics

The 2023 pedigree study discusses potential reasons for intrafamilial variability (e.g., polymorphisms in keratins/connexins and regulatory-region variants) and suggests sequencing regulatory regions, but specific validated modifier genes were not established in the retrieved text. (huang2023anovelvariant pages 7-8)

5. Environmental information

No specific environmental, lifestyle, or infectious contributors were identified in the retrieved corpus. Clouston syndrome is primarily a monogenic disorder (GJB6). (baris2008anovelgjb6 pages 1-3, huang2023anovelvariant pages 1-2)

6. Mechanism / pathophysiology (prioritizing 2024–2023)

6.1 Connexin biology and pathogenic mechanism

Connexins form gap junction channels (cell-to-cell) and can also form hemichannels (cell-to-extracellular). A key disease mechanism highlighted in recent work is hyperactive (“leaky”) hemichannel activity, enabling abnormal flux of signaling molecules such as ATP and Ca2+, which can disrupt keratinocyte proliferation/differentiation programs. (yasarbas2024connexinsinepidermal pages 15-17, yasarbas2024connexinsinepidermal pages 11-12)

6.2 Causal chain (example: Cx30-A88V)

  1. GJB6 missense variant → mutant Cx30 with altered trafficking/function (some context-dependent rescue by WT co-expression). (yasarbas2024connexinsinepidermal pages 11-12)
  2. Hyperactive hemichannels → increased ATP release and Ca2+ influx signaling. (yasarbas2024connexinsinepidermal pages 11-12, yasarbas2024connexinsinepidermal pages 15-17)
  3. Altered keratinocyte behavior (proliferation/differentiation) and adnexal effects (e.g., sebaceous gland enlargement in models) → clinical hyperkeratosis and appendage phenotypes. (yasarbas2024connexinsinepidermal pages 11-12)

6.3 Pathways / GO / cell types (suggestions)

  • Suggested GO Biological Process terms:
  • Gap junction assembly (GO:1904322)
  • Cell–cell junction organization (GO:0045216)
  • Epidermis development (GO:0008544)
  • Keratinocyte differentiation (GO:0030216)
  • ATP metabolic/signaling processes (context-dependent)
  • Suggested Cell Ontology (CL) terms:
  • Keratinocyte (CL:0000312)
  • Sebocyte (CL:0000638)

6.4 Model systems / molecular profiling

7. Anatomical structures affected

7.1 Organ/system level (primary)

7.2 Tissue/cell level (suggestions)

  • Epidermis (keratinocytes), hair follicle outer root sheath (Cx30 expression referenced in discussion), nail bed dermis with superficial vessels (reported histology in the 2023 pedigree). (huang2023anovelvariant pages 2-4)

7.3 UBERON suggestions

8. Temporal development

9. Inheritance and population

9.1 Inheritance, penetrance, expressivity

9.2 Epidemiology (available statistics)

  • Prevalence estimate (global): “affecting 1 out of 100 000 individuals” (from the 2023 paper’s introduction). (huang2023anovelvariant pages 1-2)
  • Danish clinical cohort context (1994–2013): In a retrospective study of 45 Danish ED families, Clouston syndrome was the second most common condition (n=10 patients, 4 families) among ED diagnoses captured via ICD-10 codes including Q82.4B. This is not a prevalence estimate, but provides real-world ascertainment frequency in a tertiary center cohort. (svendsen2014aretrospectivestudy pages 1-2)

9.3 Population/variant notes

10. Diagnostics

10.1 Clinical diagnosis

Clinical recognition is based on the triad (nail, hair, palmoplantar keratoderma) with preserved sweating and teeth; however, phenotypic overlap with other genodermatoses and intrafamilial variability can confound diagnosis. (kutkowskakazmierczak2015phenotypicvariabilityin pages 1-3)

10.2 Genetic testing (recommended approach based on evidence)

10.3 Histology / ancillary studies

10.4 Differential diagnosis (examples from retrieved sources)

Connexin-related and ectodermal dysplasia differential considerations include other hair–nail disorders and keratodermas; in practice, overlap can necessitate testing of multiple connexin genes. (kutkowskakazmierczak2015phenotypicvariabilityin pages 5-6, kutkowskakazmierczak2015phenotypicvariabilityin pages 1-3)

11. Outcome / prognosis

The retrieved sources do not report disease-specific survival statistics for Clouston syndrome. The condition is generally described as affecting ectodermal appendages; major morbidity relates to hair/nail/keratoderma burden and potentially pain.

Mechanistic/model evidence indicates mutant Cx30 can drive proliferative epidermal pathology in vivo, which is relevant to long-term monitoring, but Clouston-specific carcinoma risk statistics were not found in the retrieved corpus. (yasarbas2024connexinsinepidermal pages 11-12)

12. Treatment

12.1 Current standard of care

No disease-modifying therapy for Clouston syndrome was identified in the retrieved sources. Management is therefore inferred to be supportive/symptomatic (e.g., keratoderma care; nail care; pain management), but specific regimens were not detailed in the extracted texts.

12.2 Recent developments / experimental therapeutics (2024–2023 prioritized)

A major 2024 development theme is targeting connexin hemichannels (and related connexin-directed strategies) for connexinopathies.

  • Hemichannel-blocking antibody approach (preclinical, Clouston model):
  • A 2024 review reports that the monoclonal antibody abEC1.1 “also blocked the Cx30-A88V hyperactive hemichannels in Clouston syndrome mouse model,” and that topical/systemic administration reduced skin cell proliferation and sebaceous gland size (supporting hemichannel blockade as a candidate strategy). (yasarbas2024connexinsinepidermal pages 15-17)
  • Allele-specific RNA interference / antisense strategies (platform approaches; not Clouston-specific clinical trials):
  • The same 2024 review summarizes allele-specific RNAi and antisense oligonucleotide approaches used in related dominant skin disorders and highlights their promise for single-nucleotide pathogenic variants. (yasarbas2024connexinsinepidermal pages 15-17)

12.3 MAXO term suggestions (supportive mapping)

13. Prevention

Primary prevention is not applicable for an autosomal dominant Mendelian disorder except via reproductive options.

Secondary/tertiary prevention: - Cascade testing in families and early diagnosis to guide supportive care and anticipate complications is supported by the emphasis on molecular confirmation and pedigree evaluation. (huang2023anovelvariant pages 2-4, kutkowskakazmierczak2015phenotypicvariabilityin pages 7-8)

14. Other species / natural disease

No naturally occurring non-human Clouston syndrome analog was identified in the retrieved corpus.

15. Model organisms

  • Mouse model (Cx30-A88V): used to study phenotype and test hemichannel-blocking approaches; recapitulated palmoplantar hyperkeratosis and sebaceous gland enlargement (and deafness in mice). (yasarbas2024connexinsinepidermal pages 11-12)

Notes on evidence gaps (important for knowledge base curation)

  • Orphanet ID, MeSH ID, and MONDO ID were not extractable from the retrieved full-text literature in this run; direct database lookups would be required for completeness.
  • Clouston-specific standardized QoL measures, penetrance estimates, and robust population prevalence/incidence are limited in the retrieved corpus; one prevalence estimate (1/100,000) is provided in the 2023 pedigree paper introduction. (huang2023anovelvariant pages 1-2)

Key recent sources (URLs and publication dates)

References

  1. (huang2023anovelvariant pages 1-2): Hequn Huang, Mengyun Chen, Xia Liu, Xixi Xiong, Lanbo Zhou, Zhonglan Su, Yan Lu, and Bo Liang. A novel variant in the gjb6 gene in a large chinese family with a unique phenotype of clouston syndrome. Frontiers of Medicine, 17:330-338, Jan 2023. URL: https://doi.org/10.1007/s11684-022-0933-2, doi:10.1007/s11684-022-0933-2. This article has 1 citations.

  2. (baris2008anovelgjb6 pages 1-3): Hagit N. Baris, Abraham Zlotogorski, G. Peretz-Amit, V. Doviner, Mordechai Shohat, H. Reznik‐Wolf, and E. Pras. A novel gjb6 missense mutation in hidrotic ectodermal dysplasia 2 (clouston syndrome) broadens its genotypic basis. British Journal of Dermatology, 159:1373-1376, Dec 2008. URL: https://doi.org/10.1111/j.1365-2133.2008.08796.x, doi:10.1111/j.1365-2133.2008.08796.x. This article has 47 citations and is from a highest quality peer-reviewed journal.

  3. (yasarbas2024connexinsinepidermal pages 15-17): S. Suheda Yasarbas, Ece Inal, M. Azra Yildirim, Sandrine Dubrac, Jérôme Lamartine, and Gulistan Mese. Connexins in epidermal health and diseases: insights into their mutations, implications, and therapeutic solutions. Frontiers in Physiology, May 2024. URL: https://doi.org/10.3389/fphys.2024.1346971, doi:10.3389/fphys.2024.1346971. This article has 20 citations.

  4. (svendsen2014aretrospectivestudy pages 1-2): M. Svendsen, E. Henningsen, J. Hertz, Dorthe Vestergaard Grejsen, and A. Bygum. A retrospective study of clinical and mutational findings in 45 danish families with ectodermal dysplasia. Acta dermato-venereologica, 94 5:531-3, Feb 2014. URL: https://doi.org/10.2340/00015555-1799, doi:10.2340/00015555-1799. This article has 19 citations and is from a domain leading peer-reviewed journal.

  5. (peschel2024differentialdiagnostischeeinordnungektodermaler pages 22-23): Nicolai Peschel. Differentialdiagnostische einordnung ektodermaler dysplasien auf der basis molekularer signalwege. Text, Jan 2024. URL: https://doi.org/10.25593/open-fau-805, doi:10.25593/open-fau-805. This article has 0 citations and is from a peer-reviewed journal.

  6. (kutkowskakazmierczak2015phenotypicvariabilityin pages 1-3): Anna Kutkowska-Kaźmierczak, Katarzyna Niepokój, Katarzyna Wertheim-Tysarowska, Aleksandra Giza, Maria Mordasewicz-Goliszewska, Jerzy Bal, and Ewa Obersztyn. Phenotypic variability in gap junction syndromic skin disorders: experience from kid and clouston syndromes’ clinical diagnostics. Journal of Applied Genetics, 56:329-337, Jan 2015. URL: https://doi.org/10.1007/s13353-014-0266-1, doi:10.1007/s13353-014-0266-1. This article has 18 citations and is from a peer-reviewed journal.

  7. (huang2023anovelvariant pages 2-4): Hequn Huang, Mengyun Chen, Xia Liu, Xixi Xiong, Lanbo Zhou, Zhonglan Su, Yan Lu, and Bo Liang. A novel variant in the gjb6 gene in a large chinese family with a unique phenotype of clouston syndrome. Frontiers of Medicine, 17:330-338, Jan 2023. URL: https://doi.org/10.1007/s11684-022-0933-2, doi:10.1007/s11684-022-0933-2. This article has 1 citations.

  8. (huang2023anovelvariant pages 4-7): Hequn Huang, Mengyun Chen, Xia Liu, Xixi Xiong, Lanbo Zhou, Zhonglan Su, Yan Lu, and Bo Liang. A novel variant in the gjb6 gene in a large chinese family with a unique phenotype of clouston syndrome. Frontiers of Medicine, 17:330-338, Jan 2023. URL: https://doi.org/10.1007/s11684-022-0933-2, doi:10.1007/s11684-022-0933-2. This article has 1 citations.

  9. (kutkowskakazmierczak2015phenotypicvariabilityin pages 3-5): Anna Kutkowska-Kaźmierczak, Katarzyna Niepokój, Katarzyna Wertheim-Tysarowska, Aleksandra Giza, Maria Mordasewicz-Goliszewska, Jerzy Bal, and Ewa Obersztyn. Phenotypic variability in gap junction syndromic skin disorders: experience from kid and clouston syndromes’ clinical diagnostics. Journal of Applied Genetics, 56:329-337, Jan 2015. URL: https://doi.org/10.1007/s13353-014-0266-1, doi:10.1007/s13353-014-0266-1. This article has 18 citations and is from a peer-reviewed journal.

  10. (huang2023anovelvariant pages 7-8): Hequn Huang, Mengyun Chen, Xia Liu, Xixi Xiong, Lanbo Zhou, Zhonglan Su, Yan Lu, and Bo Liang. A novel variant in the gjb6 gene in a large chinese family with a unique phenotype of clouston syndrome. Frontiers of Medicine, 17:330-338, Jan 2023. URL: https://doi.org/10.1007/s11684-022-0933-2, doi:10.1007/s11684-022-0933-2. This article has 1 citations.

  11. (yasarbas2024connexinsinepidermal pages 11-12): S. Suheda Yasarbas, Ece Inal, M. Azra Yildirim, Sandrine Dubrac, Jérôme Lamartine, and Gulistan Mese. Connexins in epidermal health and diseases: insights into their mutations, implications, and therapeutic solutions. Frontiers in Physiology, May 2024. URL: https://doi.org/10.3389/fphys.2024.1346971, doi:10.3389/fphys.2024.1346971. This article has 20 citations.

  12. (kutkowskakazmierczak2015phenotypicvariabilityin pages 5-6): Anna Kutkowska-Kaźmierczak, Katarzyna Niepokój, Katarzyna Wertheim-Tysarowska, Aleksandra Giza, Maria Mordasewicz-Goliszewska, Jerzy Bal, and Ewa Obersztyn. Phenotypic variability in gap junction syndromic skin disorders: experience from kid and clouston syndromes’ clinical diagnostics. Journal of Applied Genetics, 56:329-337, Jan 2015. URL: https://doi.org/10.1007/s13353-014-0266-1, doi:10.1007/s13353-014-0266-1. This article has 18 citations and is from a peer-reviewed journal.

  13. (kutkowskakazmierczak2015phenotypicvariabilityin pages 7-8): Anna Kutkowska-Kaźmierczak, Katarzyna Niepokój, Katarzyna Wertheim-Tysarowska, Aleksandra Giza, Maria Mordasewicz-Goliszewska, Jerzy Bal, and Ewa Obersztyn. Phenotypic variability in gap junction syndromic skin disorders: experience from kid and clouston syndromes’ clinical diagnostics. Journal of Applied Genetics, 56:329-337, Jan 2015. URL: https://doi.org/10.1007/s13353-014-0266-1, doi:10.1007/s13353-014-0266-1. This article has 18 citations and is from a peer-reviewed journal.